Novavax Inc said on Friday that it will begin developing a version of the Covid-19 vaccine that targets variants detected in South Africa and will be ready for testing and production in the coming weeks.
The company’s Covid-19 shots contain the actual version of a viral peaplomer that can’t cause illness but can provoke the immune system. Vaccine developers said they started developing pesplomers specifically based on the known gene sequence B.1.1.529 of the mutant. “The first work will take a few weeks,” a spokeswoman for the company said.
The Novavax vaccine received its first emergency use approval in Indonesia earlier this month, followed by the Philippines.
Pharmaceutical giants can also apply for approval of the coronavirus vaccine in the EU and make a decision “within a few weeks.” If approved, the jab will be the fifth approved for use within the EU. The other four are created by Pfizer / BioNTech. , AstraZeneca / Oxford, Moderna, Johnson & Johnson.
According to the European Medicines Agency, the evaluation of vaccines sold under the brand name Nuvaxovid will be carried out “under an accelerated timeline.”
The drug watchdog may be issued a marketing approval opinion within a few weeks if “the data submitted is robust and complete enough to demonstrate the efficacy, safety and quality of the vaccine”. Said.
“If the EMA concludes that the benefits of Nuvaxovid outweigh the risks of protection from Covid-19, we recommend giving conditional marketing approval.”
Nuvaxovid, which works differently from other vaccines, contains small particles made from a protein version on the surface of laboratory-made coronavirus peplomer proteins. It also contains substances that help enhance the immune response to the vaccine.
“When a person is vaccinated, their immune system identifies protein particles as foreign substances and creates a natural defense (antibodies and T cells) against them,” EMA said.
If the vaccinated person later comes into contact with the coronavirus, “the immune system recognizes the viral spike protein and is ready to attack it.” “Antibodies and immune cells work together to produce Covid-19. It can be killed. The virus prevents the body from invading cells and destroys infected cells. “
Novavax said in a statement that the vaccination plan would require intramuscular injection of two 0.5 ml jabs at 21-day intervals.
Nuvaxovid added that it is stored at 2-8 degrees Celsius and “enables existing vaccine supply and use of cold chain channels.” Novavax, a Maryland-based company, states that the vaccine is 90% effective against Covid-19. Based on North American studies.
Read all the latest news, latest news, coronavirus news here. Follow us on Facebook, twitter And telegram.
Novavax states that it manufactures the Covid-19 vaccine to protect it from the new “Omicron” variant.
Source link Novavax states that it manufactures the Covid-19 vaccine to protect it from the new “Omicron” variant.